MRKR - Marker Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

4.782M

Cash

18.12M

Avg Qtr Burn

-6.724M

Short % of Float

3.51%

Insider Ownership

12.31%

Institutional Own.

23.83%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MT-401 Details Acute myeloid leukemia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-601 Details Non-Hodgkin lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MT-601 (w/ chemotherapy) Details Pancreatic cancer	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.